Navigation Links
Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
Date:6/28/2010

age 12 to 45 with new-onset type 1 diabetes. In the confirmatory study, otelixizumab is administered as a single course, given not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes.  The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell function that has been endorsed by the U.S. Food and Drug Administration (FDA) at 12 months after dosing.  Maintenance of beta cell function has been associated with improved glycemic control (HbA1c levels), fewer hypoglycemic events, fewer hyperglycemic excursions, and a reduction in long-term disease complications in established type 1 diabetes patients, as referenced in the Diabetes Control and Complications Trial (DCCT).

"Tolerx is aggressively moving forward in our clinical development of otelixizumab.  We are excited by the potential of this novel drug candidate to change the type 1 diabetes treatment paradigm by inhibiting disease progression and perhaps halting the disease by inducing an immunologic remission," said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx.  "The first patients have been dosed in the DEFEND-2 study, and we believe our study is designed with the robustness and rigor to confirm the efficacy and safety of otelixizumab in a broad patient population."

For additional information about DEFEND-2, please visit www.DefendAgainstDiabetes.com.

About Type 1 Diabetes

Diabetes (medically known as diabetes mellitus) is the name given to disorders in which the body has difficulty regulating its blood glucose (sugar) level. Ther
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Cynosure, Inc. (Nasdaq: ... light-based aesthetic treatment systems for high-volume applications, today reported ... 2014. Second-quarter 2014 financial results incorporate the acquisition of ... 2013. Second-Quarter 2014 Financial Highlights ... $72.6 million , Non-GAAP net income of $7.1 ...
(Date:7/29/2014)... Texas , July 29, 2014  Novation, ... new web-based applications with breakthrough interactive features that ... workflows for members of Children,s Hospital Association.  ... the Novation Optimize Solutions umbrella – Value Analysis, ... how Novation helps organizations address the most critical ...
(Date:7/29/2014)... July 29, 2014  The BioFusionary Corporation, Inc. ... a proprietary electromagnetic induction platform with aesthetic and ... agreement under which TBC will merge with ... in an all-stock transaction. Upon completion ... on the Australian Stock Exchange under the code ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3
... WOODCLIFF LAKE, N.J., Nov. 3, 2010 Par Pharmaceutical Companies, ... the third quarter ended September 30, 2010. For ... total revenues of $234.4 million and income from continuing operations ... included a $2.0 milestone payment to Tris Pharma, Inc., a ...
... 2010 Regado Biosciences, Inc., a privately held company ... agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior ... at the American College of Chest Physicians (ACCP) Coagulation ... Vancouver, BC, Canada.  The abstract is titled "Sustained Inhibition ...
Cached Medicine Technology:Par Pharmaceutical Companies Reports Third Quarter 2010 Results 2Par Pharmaceutical Companies Reports Third Quarter 2010 Results 3Par Pharmaceutical Companies Reports Third Quarter 2010 Results 4Par Pharmaceutical Companies Reports Third Quarter 2010 Results 5Par Pharmaceutical Companies Reports Third Quarter 2010 Results 6Par Pharmaceutical Companies Reports Third Quarter 2010 Results 7Par Pharmaceutical Companies Reports Third Quarter 2010 Results 8Par Pharmaceutical Companies Reports Third Quarter 2010 Results 9Par Pharmaceutical Companies Reports Third Quarter 2010 Results 10Par Pharmaceutical Companies Reports Third Quarter 2010 Results 11Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 2Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 3
(Date:7/29/2014)... Calif. (PRWEB) July 29, 2014 July ... drug abuse directly at the source? That’s the big ... an innovative prescription drug abuse risk program developed by ... hundreds of applicants worldwide to be part of ... 10-12 in San Francisco, CA. The Hive is a ...
(Date:7/29/2014)... should significantly reform the federal system for financing ... the public,s $15 billion annual investment is producing ... new report by the Institute of Medicine. ... requires little accountability, allocates funds independent of workforce ... to train physicians in the health care settings ...
(Date:7/29/2014)... HealthDay Reporter MONDAY, July 28, 2014 ... to rage throughout West Africa poses little risk to Americans, ... physical touch, and it can,t be spread by people who ... the National Center for Emerging & Zoonotic Infectious Diseases at ... a Monday afternoon news conference. Those factors -- and ...
(Date:7/29/2014)... July 29, 2014 – Silverado, a provider of ... announce that it is a Bronze winner in the 35th ... Silverado Through a Child's Eye and Silverado Resident ... Through a Child's Eye , seven-year-old Mia Sandoval shares her ... Place, a memory care community in Los Angeles. The feel-good ...
(Date:7/29/2014)... July 29, 2014 Doug and Sandra Williams ... years and selling their grow-your-own log kits for almost that ... Williams’ diet and a treat for their guests. A ... perspective to the Lost Creek Mushroom Farm online coverage. , ... chefs, but soon turned to selling the logs instead of ...
Breaking Medicine News(10 mins):Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 2Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 3Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 2Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 3Health News:CDC Downplays Ebola's Threat to the United States 2Health News:CDC Downplays Ebola's Threat to the United States 3Health News:CDC Downplays Ebola's Threat to the United States 4Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Lost Creek Mushroom Farm Cooks Up a Company Dish from Shiitake Mushrooms Grown on Logs With Grow-Your-Own Log Kits 2Health News:Lost Creek Mushroom Farm Cooks Up a Company Dish from Shiitake Mushrooms Grown on Logs With Grow-Your-Own Log Kits 3Health News:Lost Creek Mushroom Farm Cooks Up a Company Dish from Shiitake Mushrooms Grown on Logs With Grow-Your-Own Log Kits 4
... ... aftershave, beard inhibitor, and SPF29 sun block spray. , ... (PRWEB) January 27, 2010 -- Hey Dude Skin Care ™, ... an outstanding array of premium skin care products targeted at the unique protection, repair and ...
... CHAIRMAN , NEW YORK , Jan. 27 ... University announced today that William H. Foster , PhD, Dean ... Service, will become President and Chief Executive Officer of CASA on ... former U.S. Secretary of Health, Education, and Welfare who founded CASA in ...
... , , PHOENIX ... Eating and Anxiety Disorders ( http://www.remudaranch.com ) and MASK (Mothers ... teachers and students about eating disorders and related issues. , ... trained by an organization of the caliber of Remuda Ranch," ...
... , , NEW YORK , Jan. 27 ... $250,000 grant to the Clinton Health Access Initiative (CHAI), a ... in 2002. The grant will ensure the continuation of HIV/AIDS ... of the devastating January 12 earthquake. , ...
... , , LOS ANGELES , Jan. 27 ... more information about the IDEAL breast implants on his blog. He discussed ... would be available to the public for a clinical trial. , Board-certified ... of the new IDEAL breast implants. These implants are known to have ...
... woman who suggests using a condom makes no difference to ... suggests it makes a difference. If she highlights her sexuality ... and fun activity, other women judge her more harshly than ... or shares her concerns about sexually transmitted infections. Dr. Michelle ...
Cached Medicine News:Health News:Hey Dude Skin Care™ Rolls Out Line of Premium Men's Skin Care Products 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 3Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 4Health News:Remuda Ranch, Programs for Eating and Anxiety Disorders, and MASK (Mothers Awareness on School-Age Kids), Partner to Help Educate Parents, Teachers and Students About Eating Disorders 2Health News:Remuda Ranch, Programs for Eating and Anxiety Disorders, and MASK (Mothers Awareness on School-Age Kids), Partner to Help Educate Parents, Teachers and Students About Eating Disorders 3Health News:Ford Foundation Commits $250,000 to Support HIV/AIDS Services in Haiti 2Health News:Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants 2Health News:Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants 3Health News:Condom or no condom? It's not what you say, it's how you say it 2
... Certified by an independent laboratory ... of Federal Standard 209E. Ergonomic ... fatique and back injuries. Clean ... requirements. Static-control chairs feature dissipative ...
... SCE offers a full line of ... manufacturing and laboratory environments. Every SCE product ... / safety requirements. Now you can have ... hazardous acid / corrosive chemicals and materials ...
... Genie is an all-in-one rotator/rocker with ... five different mixing motions: rotating, ... well as a combination of all ... portion of the Vibraotme Roto-Shake Genie ...
... 55S Rocking Shaker provides the exact ... membranes. The very slow to fast ... tilt provide a gentle wave motion ... and blotted membranes to achieve faster, ...
Medicine Products: